| Disease ID | Disease name | Source of annotation with PRKCG | OMIM link | Number of associated genes | genes |
|---|---|---|---|---|---|
| PS164400 | SPINOCEREBELLAR ATAXIA | ClinVar, OMIM, HUMSAVAR | link to OMIM | 31 | ATXN10, ATXN2, SCYL1, PDYN, ELOVL5, PRKCG, TRPC3, ATXN8OS, NOP56, ATXN8, TBP, PPP2R2B, ELOVL4, PLEKHG4, ATXN7, AFG3L2, BEAN1, CACNA1A, ATXN1, TTBK2, KCND3, CACNA1G, TMEM240, ATXN3, KCNC3, SPTBN2, TGM6, CCDC88C, FGF14, ITPR1, EEF2 |
Download the gene annotation in CSV format
| KEGG pathway | KEGG ID | KEGG IC |
|---|---|---|
| GABAergic synapse | hsa04727 | 6.24 |
| Natural killer cell mediated cytotoxicity | hsa04650 | 5.53 |
| Calcium signaling pathway | hsa04020 | 5.22 |
| Glioma | hsa05214 | 6.66 |
| Tight junction | hsa04530 | 5.53 |
| Long-term potentiation | hsa04720 | 6.64 |
| Retrograde endocannabinoid signaling | hsa04723 | 6.03 |
| Leukocyte transendothelial migration | hsa04670 | 5.74 |
| Cholinergic synapse | hsa04725 | 5.88 |
| Choline metabolism in cancer | hsa05231 | 6.09 |
| Focal adhesion | hsa04510 | 4.92 |
| Serotonergic synapse | hsa04726 | 5.84 |
| HIF-1 signaling pathway | hsa04066 | 5.9 |
| Dopaminergic synapse | hsa04728 | 5.69 |
| Oxytocin signaling pathway | hsa04921 | 5.4 |
| Endocrine and other factor-regulated calcium reabsorption | hsa04961 | 7.12 |
| Aldosterone-regulated sodium reabsorption | hsa04960 | 7.41 |
| African trypanosomiasis | hsa05143 | 7.68 |
| Amoebiasis | hsa05146 | 5.82 |
| Long-term depression | hsa04730 | 6.74 |
| Wnt signaling pathway | hsa04310 | 5.49 |
| Hepatitis B | hsa05161 | 5.52 |
| Vascular smooth muscle contraction | hsa04270 | 5.74 |
| Gap junction | hsa04540 | 6.24 |
| VEGF signaling pathway | hsa04370 | 6.77 |
| Proteoglycans in cancer | hsa05205 | 5.02 |
| MicroRNAs in cancer | hsa05206 | 5.38 |
| Pathways in cancer | hsa05200 | 3.98 |
| Phosphatidylinositol signaling system | hsa04070 | 6.38 |
| Rap1 signaling pathway | hsa04015 | 4.97 |
| Insulin secretion | hsa04911 | 6.18 |
| Melanogenesis | hsa04916 | 5.97 |
| ErbB signaling pathway | hsa04012 | 6.15 |
| Fc gamma R-mediated phagocytosis | hsa04666 | 6.21 |
| MAPK signaling pathway | hsa04010 | 4.63 |
| Thyroid hormone synthesis | hsa04918 | 6.56 |
| Thyroid hormone signaling pathway | hsa04919 | 5.82 |
| mTOR signaling pathway | hsa04150 | 6.72 |
| Salivary secretion | hsa04970 | 6.23 |
| Gastric acid secretion | hsa04971 | 6.48 |
| Pancreatic secretion | hsa04972 | 6.07 |
| Vibrio cholerae infection | hsa05110 | 6.86 |
| Non-small cell lung cancer | hsa05223 | 6.88 |
| Morphine addiction | hsa05032 | 6.15 |
| Ras signaling pathway | hsa04014 | 4.9 |
| Amphetamine addiction | hsa05031 | 6.62 |
| Inflammatory mediator regulation of TRP channels | hsa04750 | 6.07 |
| Circadian entrainment | hsa04713 | 6.11 |
| Glutamatergic synapse | hsa04724 | 5.84 |
| REACTOME pathway | REACTOME ID | REACTOME IC |
|---|---|---|
| Phospholipase C-mediated cascade; FGFR2 | R-HSA-5654221 | 7.37 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 7.85 |
| DAG and IP3 signaling | R-HSA-1489509 | 7.98 |
| Phospholipase C-mediated cascade; FGFR3 | R-HSA-5654227 | 7.52 |
| Ca-dependent events | R-HSA-111996 | 8.18 |
| Phospholipase C-mediated cascade; FGFR4 | R-HSA-5654228 | 7.46 |
| G alpha (z) signalling events | R-HSA-418597 | 7.46 |
| Immune System | R-HSA-168256 | 2.37 |
| Trafficking of AMPA receptors | R-HSA-399719 | 8.08 |
| Downstream signal transduction | R-HSA-186763 | 4.65 |
| Calmodulin induced events | R-HSA-111933 | 8.28 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 4.71 |
| CaM pathway | R-HSA-111997 | 8.28 |
| Signalling by NGF | R-HSA-166520 | 4.23 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 5.15 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 6.59 |
| Signaling by EGFR | R-HSA-177929 | 4.59 |
| Phospholipase C-mediated cascade: FGFR1 | R-HSA-5654219 | 7.43 |
| Neuronal System | R-HSA-112316 | 4.82 |
| Signaling by GPCR | R-HSA-372790 | 2.68 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 4.71 |
| Transmission across Chemical Synapses | R-HSA-112315 | 5.28 |
| Signaling by FGFR4 | R-HSA-5654743 | 4.69 |
| Signaling by FGFR3 | R-HSA-5654741 | 4.69 |
| Signaling by FGFR | R-HSA-190236 | 4.67 |
| GPCR downstream signaling | R-HSA-388396 | 3.07 |
| beta-catenin independent WNT signaling | R-HSA-3858494 | 5.83 |
| Innate Immune System | R-HSA-168249 | 3.17 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 8.98 |
| Signaling by PDGF | R-HSA-186797 | 4.53 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 7.89 |
| DAP12 signaling | R-HSA-2424491 | 4.64 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 4.71 |
| Disinhibition of SNARE formation | R-HSA-114516 | 10.66 |
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | R-HSA-112314 | 5.85 |
| NGF signalling via TRKA from the plasma membrane | R-HSA-187037 | 4.51 |
| PLC-gamma1 signalling | R-HSA-167021 | 7.89 |
| Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity | R-HSA-399721 | 8.08 |
| Signaling by Wnt | R-HSA-195721 | 4.79 |
| PLC beta mediated events | R-HSA-112043 | 7.52 |
| G-protein mediated events | R-HSA-112040 | 7.49 |
| Signaling by FGFR2 | R-HSA-5654738 | 4.68 |
| Signaling by FGFR1 | R-HSA-5654736 | 4.69 |
| Opioid Signalling | R-HSA-111885 | 6.64 |
| PCP/CE pathway | R-HSA-4086400 | 6.47 |
| DAP12 interactions | R-HSA-2172127 | 4.56 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 4.71 |
| Signaling by ERBB2 | R-HSA-1227986 | 4.66 |
| Hemostasis | R-HSA-109582 | 3.98 |
| Signal Transduction | R-HSA-162582 | 1.78 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 9.08 |
| GO term | GO ID | GO IC |
|---|---|---|
| purine ribonucleoside triphosphate binding | GO:0035639 | 2.22 |
| calcium-dependent protein kinase C activity | GO:0004698 | 8.35 |
| binding | GO:0005488 | 0.18 |
| nucleotide binding | GO:0000166 | 1.96 |
| protein kinase C activity | GO:0004697 | 6.97 |
| heterocyclic compound binding | GO:1901363 | 1.06 |
| nucleoside phosphate binding | GO:1901265 | 1.96 |
| nucleoside binding | GO:0001882 | 2.21 |
| cation binding | GO:0043169 | 1.4 |
| transition metal ion binding | GO:0046914 | 2.48 |
| ion binding | GO:0043167 | 1.36 |
| protein serine/threonine kinase activity | GO:0004674 | 3.64 |
| transferase activity | GO:0016740 | 1.95 |
| protein serine/threonine/tyrosine kinase activity | GO:0004712 | 6.07 |
| purine nucleoside binding | GO:0001883 | 2.22 |
| protein kinase activity | GO:0004672 | 3.27 |
| purine nucleotide binding | GO:0017076 | 2.19 |
| metal ion binding | GO:0046872 | 1.41 |
| ATP binding | GO:0005524 | 2.43 |
| kinase activity | GO:0016301 | 2.93 |
| ribonucleoside binding | GO:0032549 | 2.22 |
| small molecule binding | GO:0036094 | 1.89 |
| catalytic activity | GO:0003824 | 1.05 |
| calcium-dependent protein kinase activity | GO:0010857 | 7.25 |
| adenyl nucleotide binding | GO:0030554 | 2.4 |
| carbohydrate derivative binding | GO:0097367 | 2.03 |
| organic cyclic compound binding | GO:0097159 | 1.05 |
| calcium-dependent protein serine/threonine kinase activity | GO:0009931 | 7.34 |
| phosphotransferase activity, alcohol group as acceptor | GO:0016773 | 3.08 |
| adenyl ribonucleotide binding | GO:0032559 | 2.41 |
| transferase activity, transferring phosphorus-containing groups | GO:0016772 | 2.77 |
| purine ribonucleotide binding | GO:0032555 | 2.2 |
| purine ribonucleoside binding | GO:0032550 | 2.22 |
| ribonucleotide binding | GO:0032553 | 2.19 |
| zinc ion binding | GO:0008270 | 2.66 |